Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Intas Pharmaceuticals Limited
483
•Intas Pharmaceuticals Limited•May 12, 2023

Intas Pharmaceuticals Limited – FDA 483, May 12, 2023

Record Details

This FDA Form 483 document details multiple observations from an inspection, indicating significant deficiencies in the facility's quality control and manufacturing processes.

**Key Observations:**

* **Batch Production and Control Records:** Incomplete information in batch records and identical visual inspection records for multiple operators were noted. * **Process Controls:** Inadequate controls for tablet compression and a failure to thoroughly review unexplained discrepancies were identified. * **Written Procedures:** The firm lacked adequate written procedures for production and process controls to ensure drug product identity, strength, purity, and quality. * **Aseptic Processing:** Deficiencies included inadequate validation of aseptic and sterilization processes, insufficient cleaning/disinfection systems, and inadequate environmental monitoring in aseptic areas. * **Computer Systems:** Controls over computer systems were insufficient to ensure changes to master records were made only by authorized personnel. * **Equipment Maintenance:** Routine checking of automatic, mechanical, and electronic equipment was not performed per a written program. Equipment and utensils were not maintained at appropriate intervals, and equipment design was not appropriate for its intended use. * **Quality Control Unit:** Responsibilities and procedures of the quality control unit were not fully followed. * **Annual Quality Standards Review:** Procedures for annual quality standards evaluation were deficient, lacking review of a representative number of approved and rejected batches. * **Microbiological Contamination:** Procedures to prevent objectionable microorganisms in non-sterile drug products were inadequate. *

Company
Intas Pharmaceuticals Limited
Inspection date
May 12, 2023
Product type
Tobacco
People
  • Arsen Karapetyan
  • Rita Kabaso
  • Justin A. Boyd (Research Specialist II)
  • Asen Karapetyan
View Company Profile

ID · 439bcecd-27da-49d0-b32b-ce7d8d990792

Violation Codes3
21 CFR 21021 CFR 21121 CFR 331(c)

Full citation text and observation details available on the Dashboard.

Other documents for Intas Pharmaceuticals Limited
  • WARNING_LETTER - 2025-09-17September 17, 2025
  • 483 - 2025-02-14February 14, 2025
  • 483 - 2024-01-24January 24, 2024
  • 483 - 2023-12-07December 7, 2023
  • 483 - 2022-12-02December 2, 2022

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Intas Pharmaceuticals Limited
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.